AMNEAL PHARMACEUTICALS INC

AMRX is the ticker for Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company. It develops, manufactures, and markets generic medicines, specialty branded pharmaceuticals, and over-the-counter products. Its portfolio spans complex generics, injectables, and treatments in areas such as central nervous system and endocrine disorders. The company operates primarily in the United States and select international markets.

Recent performance data for AMRX, including its latest price change and percentage move, is displayed on this page. Performance can vary with quarterly results, product approvals, and broader market conditions. For the most current figures, refer to the live quote and performance chart above.

Evaluating AMRX involves comparing metrics such as price-to-earnings, price-to-sales, and enterprise value-to-EBITDA against peers in the generic and specialty pharmaceutical space. Growth trends, margin stability, debt levels, and pipeline prospects also matter. Current valuation ratios for AMRX are shown on this page, so use those live figures rather than static estimates.

AMRX can trade in pre-market and after-hours sessions on U.S. exchanges, though volume is typically lower and spreads wider. Extended-hours trading depends on your broker's platform and may involve additional risks. Regular session hours are 9:30 a.m. to 4:00 p.m. ET. Check your brokerage for AMRX extended-hours availability.

Amneal Pharmaceuticals does not currently pay a regular cash dividend on AMRX common stock. Instead, the company has focused on reinvesting capital into its generics and specialty businesses. Dividend policies can change over time, so verify the latest status and any declared distributions on this AMRX page or in company filings.

Key risks for AMRX include pricing pressure in generic drugs, regulatory and manufacturing compliance issues, product concentration, and competition from other pharmaceutical manufacturers. Litigation, supply chain disruptions, and changes in healthcare policy can also affect results. Because these factors can shift, review AMRX's latest filings and the risk summary on this page for current details.